7 Best Peptides for Sarcopenia

What to Know Before Choosing a Peptide for Sarcopenia

Sarcopenia is not a single problem. It is a cluster of age-related failures happening at once: growth hormone output declines, muscle cells stop responding normally to protein and anabolic signals, the body starts producing more muscle-suppressing proteins, satellite cells lose their ability to repair tissue, and chronic low-grade inflammation accelerates breakdown faster than the body can rebuild. No single peptide addresses all of those mechanisms, and no single peptide has yet crossed the finish line in a major clinical trial demonstrating the outcome that matters most to patients, which is meaningful improvement in physical function.

That context matters before reading anything below. A compound earned a slot in this guide because people genuinely use it or are actively discussing it for sarcopenia, not because it is FDA-approved or because it has deep clinical trial data behind it. FDA-approved compounds, telemedicine-prescribed compounds, and research-only compounds are all represented here, and evidence strength is described honestly inside each entry rather than used as a filter. Some of these have Phase II human data. Some have only animal studies. One has almost nothing in publicly searchable sources and belongs here because people are actively seeking it out.

The entries are numbered. Those numbers are a spine for the list, not a verdict. The order reflects how prominently each compound appears in research and in documented real-world use for sarcopenia. It does not mean compound one is a better choice than compound four for you. The right choice depends on your specific situation, and that personalized decision belongs in a conversation with a physician and a tool built to handle individual variables.

1. MK-677: The Most Clinically Evidenced Option

MK-677, also called ibutamoren, is not technically a peptide. It is a small molecule that mimics ghrelin, the hunger-signaling hormone, by binding to the ghrelin receptor in the pituitary gland. That binding triggers the pituitary to release endogenous growth hormone. More growth hormone means more downstream IGF-1, the insulin-like growth factor that activates the cellular machinery responsible for muscle protein synthesis. The appeal for sarcopenia is direct: one of the central drivers of age-related muscle loss is a steady decline in GH and IGF-1 output, sometimes called somatopause, and MK-677 addresses that decline at its source without requiring injection, which distinguishes it from every other compound in this guide.

Of all the compounds listed here, MK-677 has the most published human data. A Phase II clinical trial found it produced a meaningful increase in lean body mass, roughly 1.1 kilograms above placebo over the study period. That is a real finding, and it places MK-677 ahead of most of the field in terms of human evidence for muscle-related outcomes. The limitation worth understanding clearly is that the trial did not demonstrate a significant improvement in physical function, which is the clinical benchmark that actually defines treatment success in sarcopenia. Lean mass and functional strength are related but not identical, and most investigational compounds, including MK-677, have consistently increased the former without reliably moving the latter.

MK-677 is not FDA-approved for sarcopenia or any muscle-wasting indication. It is available as a research chemical and also appears in gray-market supplement formulations. Because it works through the ghrelin receptor, it reliably increases appetite, which can lead to fat gain alongside any lean mass benefit. It also has a documented tendency to reduce insulin sensitivity and elevate blood glucose, a consideration that carries real weight for older adults who may already have metabolic vulnerabilities. Edema and joint discomfort are commonly reported. Its oral bioavailability makes it a frequent starting point in community protocols for people who are not yet comfortable with injectable compounds.

2. CJC-1295: For Sustained GH Pulse Support

CJC-1295 is a synthetic analog of growth hormone releasing hormone, the signal the hypothalamus sends to the pituitary when it wants a GH pulse. It binds GHRH receptors in the pituitary and stimulates sustained, pulsatile release of endogenous growth hormone. That downstream GH elevation drives IGF-1 upward, which activates the PI3K/Akt/mTOR signaling cascade, the pathway through which muscle cells are instructed to synthesize new protein. For sarcopenia, the logic is that restoring a more youthful GH secretion pattern counteracts the blunted anabolic signaling that allows muscle to erode over time.

CJC-1295 comes in two formulations. The version with a Drug Affinity Complex attached has a significantly extended half-life, allowing for less frequent dosing. The version without it clears faster and is almost always paired with a GHRP like Ipamorelin to achieve the combined effect of sustained baseline amplitude plus triggered individual pulses. That combination stack is the most commonly used and discussed pairing in community protocols for GH optimization in the context of aging.

No large-scale, standalone human randomized controlled trial for CJC-1295 in sarcopenia has been published. The compound is used off-label and is available via licensed compounding pharmacies under physician prescription, though the FDA has been reviewing which compounded peptides will be permitted for continued production as of 2026, meaning the regulatory situation may shift. The side effect profile includes injection site reactions, headaches, water retention, and fatigue. The longer-term theoretical risks associated with sustained GH elevation, including cardiovascular and cancer-related concerns, have not been established in controlled trials but are frequently cited as a reason for physician oversight during extended use. The evidence base here is off-label and experiential rather than condition-specific clinical data.

3. Ipamorelin: For Selective GH Release Without Cortisol Elevation

Ipamorelin is a selective ghrelin receptor agonist, and the selectivity is what sets it apart from older members of its class. Earlier growth hormone releasing peptides like GHRP-6 stimulated GH secretion but also meaningfully elevated cortisol and prolactin, hormones that work against the anabolic goal. Ipamorelin achieves similar GH pulse stimulation without those hormonal side effects, making it the preferred option in modern protocols. Its mechanism sits downstream of CJC-1295 in the GH axis: where CJC-1295 increases the amplitude baseline of GH secretion, Ipamorelin triggers the individual pulses, and the two together produce a synergistic effect on GH output that neither achieves alone.

For sarcopenia, people using Ipamorelin are targeting the same GH/IGF-1 decline that MK-677 and CJC-1295 address, but they value the cleaner hormonal profile and the ability to time pulses around sleep and training sessions. Across community protocols and user reports, the most frequently noted benefits are improved sleep quality, faster recovery from training, and gradually improving body composition over several weeks. Some users report meaningful changes in energy and healing; others report no noticeable effect beyond injection site irritation. The results are genuinely variable, and there is no controlled human trial data for sarcopenia specifically to resolve that variability.

Ipamorelin is not FDA-approved for sarcopenia. It is available via compounding pharmacies under physician prescription, with the same ongoing FDA compounding review caveat as CJC-1295. The safety data that exists comes from its use alongside other GH secretagogues rather than standalone sarcopenia trials. Headaches, nausea, and hypoglycemia risk when combined with insulin sensitizers are the commonly reported concerns. The evidence base for its sarcopenia-specific use is off-label and largely experiential, grounded in its well-understood mechanism rather than condition-specific trial outcomes.

4. IGF-1 LR3: For Targeting Anabolic Resistance Directly

IGF-1 LR3 is a modified analog of insulin-like growth factor 1, engineered with an arginine substitution at position three of the chain. That substitution prevents it from binding to the binding proteins that would otherwise quickly sequester and neutralize it in circulation, extending its active half-life dramatically compared to native IGF-1. The result is a compound that engages IGF-1 receptors on muscle cells far more persistently than the naturally occurring hormone.

Why this matters for sarcopenia is worth spelling out. One hallmark of aging muscle is anabolic resistance, the state where muscle cells have become less responsive to the anabolic signals that would normally trigger repair and growth. That resistance sits partly at the IGF-1 receptor level. IGF-1 LR3 directly activates those receptors and engages the PI3K/Akt/mTOR pathway, driving protein synthesis, while also inhibiting FoxO3a, a transcription factor that, when active, switches on the proteins responsible for breaking muscle down. In animal and in vitro studies, it has also been shown to support restoration of satellite cell density, the stem cell population that repairs and builds muscle fibers. The mechanistic rationale for sarcopenia is among the strongest of any compound in this guide.

The clinical reality is considerably more cautious. No large-scale human randomized controlled trial for IGF-1 LR3 in sarcopenia has been published. This is a research compound, not available through compounding pharmacies for general use, and not FDA-approved for any muscle-related indication. The safety concerns are significant enough to state plainly: IGF-1 has insulin-like effects, and the extended activity window of the LR3 form creates real hypoglycemia risk. Seizures from blood glucose crashes have been reported in the broader IGF-1 derivative literature. Chronic use raises concerns about liver and kidney stress. For older adults who already have metabolic fragility, those risks are not abstract. The evidence base is preclinical and mechanistic, and physician involvement before any use is a genuine requirement, not a formality.

5. Follistatin 344: For Directly Targeting Myostatin

Follistatin 344 targets sarcopenia at a mechanism the other compounds in this guide do not reach. Myostatin and activin-A are proteins the body produces to suppress skeletal muscle growth, acting as the built-in brake on hypertrophy. In aging muscle, both are expressed at elevated levels, which contributes directly to why muscle becomes harder to build and easier to lose with age. Follistatin neutralizes those suppressors by binding to them, removing the brake. In aged satellite cells specifically, myostatin maintains a differentiation block mediated by the SMAD2/3 signaling pathway, preventing the stem cells that repair muscle from doing their job. Follistatin reverses that block.

The mechanistic case is compelling. The clinical picture is not yet there. No published large-scale human clinical trial exists for Follistatin 344 in sarcopenia. The class of interventions it belongs to does have some human data: bimagrumab, an antibody that blocks the same ActRII/myostatin signaling pathway, was studied in Phase II trials and produced increases in lean mass alongside decreases in fat mass. However, bimagrumab showed no significant improvement in physical function compared to placebo, the outcome that matters most clinically. A separate cautionary note comes from ACE-031, a myostatin trap targeting the same pathway, which was halted in clinical trials due to safety concerns. Those are class-level data points rather than direct evidence about Follistatin 344 itself, but they illustrate that blocking myostatin in humans has not yet translated to the functional improvements the mechanism predicts.

Follistatin 344 is a research compound with no established human safety profile, no FDA approval, and no compounding pharmacy channel. Its presence in sarcopenia-specific community discussion is less prominent than the compounds higher on this list, with most of its real-world use concentrated in bodybuilding and biohacking contexts focused on general muscle growth. The evidence here is preclinical and mechanistic. Anyone approaching it should carry that honest picture into the conversation.

6. Sermorelin: The Physician-Supervised GH Secretagogue

Sermorelin is a synthetic analog of growth hormone releasing hormone, the same class as CJC-1295 but shorter-acting and with a considerably longer regulatory history. It is FDA-approved for growth hormone deficiency in children, which gives it a distinct status compared to most of the compounds in this guide, and it is available through compounding pharmacies for adult off-label use under physician supervision. That prescription pathway and the physician involvement it entails make Sermorelin the most clinically accessible of the GH secretagogues for people working through a healthcare provider rather than a research chemical channel.

For sarcopenia, Sermorelin is often incorporated as part of a combination approach alongside Ipamorelin and CJC-1295, a pairing sometimes called the GH secretagogue trio in clinical and community settings. The claimed benefits track closely with the other GH-stimulating compounds: improved sleep quality, better recovery from training, gradual changes in body composition, and increased IGF-1. Community reports consistently emphasize the sleep and recovery improvements as the most reliably noticed effects, with lean mass and strength changes tending to emerge more slowly and with more individual variation.

Sermorelin has not been studied in a large-scale randomized controlled trial for sarcopenia specifically. Its off-label use for adult muscle health sits outside the approved pediatric indication, and the human data on its effects in older adults with muscle loss is limited rather than absent. The safety profile under physician supervision is the most established of the injectable GH secretagogues in this list, given its FDA approval history, but that history does not eliminate the theoretical risks of sustained GH axis stimulation in an older adult population. Flu-like symptoms are among the side effects most commonly reported in off-label adult use.

7. Gotratix: Community Interest With Limited Searchable Evidence

Gotratix surfaces in conversations about peptides for sarcopenia and muscle loss, and that real-world discussion earns it a place here. The published evidence available in searchable sources as of 2026, however, is limited enough that characterizing it at the same depth as the other entries in this guide is not possible without risk of inaccuracy.

No large-scale human clinical trial data for Gotratix in sarcopenia has been identified in publicly available research as of 2026. Its mechanism of action, precise formulation, and active constituents are not sufficiently described in accessible literature to lay out with confidence. It may represent a proprietary or branded formulation, an emerging research compound with limited indexing, or a compound known under different names in different regions. What exists in the searchable public record points to community interest rather than a clinical evidence base.

The honest framing for Gotratix at this stage is that it belongs on the map of what people are looking into for sarcopenia. Anyone considering it would need to pursue targeted, current research to understand what specifically they are looking at, what the active constituents are, and what safety data, if any, exists for human use. That investigation warrants physician involvement before any use, given the absence of a documented human safety profile.

How These Peptides Compare

Frequently Asked Questions

Is any peptide FDA-approved specifically for sarcopenia?

No. As of 2026, there is no FDA-approved pharmacological treatment specifically for sarcopenia. The evidence-based standard of care remains resistance training combined with adequate protein intake. Several investigational compounds are in clinical development, with one advancing toward a Phase III trial, but none has received approval. The compounds in this guide are used off-label, through compounding pharmacies, or as unregulated research chemicals.

Why do some compounds show lean mass gains but not functional improvement?

This is one of the most consistent patterns across sarcopenia research. Lean mass and physical function, meaning things like walking speed, grip strength, and the ability to rise from a chair, are related but not the same thing. A compound can add measurable lean tissue without that tissue being the kind of functional, well-coordinated muscle that translates to better movement. Clinical definitions of treatment success in sarcopenia require demonstrated functional improvement, not just a shift in body composition, which is why Phase II results showing lean mass gains without functional improvement are considered insufficient for regulatory approval.

Are these compounds safe for older adults specifically?

The safety picture for research-grade peptides in older adults is largely unknown, and the unknowns carry real weight. Older adults often have metabolic vulnerabilities, take multiple medications with interaction potential, and may have conditions that make specific compounds considerably more risky. IGF-1 LR3, for example, carries a hypoglycemia risk that is more dangerous for someone with existing metabolic fragility than for a younger, healthy user. Major health organizations have advised older adults to avoid unapproved peptides given the absence of established dosing, safety profiles, and quality assurance for unregulated compounds. Physician oversight is a practical requirement here, not a formality.

What is the difference between a GHRH analog and a ghrelin mimetic?

Both stimulate growth hormone release, but through different receptor systems. GHRH analogs like CJC-1295 and Sermorelin bind the GHRH receptor in the pituitary, mimicking the hypothalamus's natural signal to produce and release GH. Ghrelin mimetics like MK-677 and Ipamorelin bind the ghrelin receptor, a separate pathway that also triggers GH secretion. The two systems work synergistically, which is why pairing a GHRH analog with a ghrelin mimetic produces a larger GH response than either alone. A practical difference is that MK-677 is taken orally while the GHRH analogs require subcutaneous injection.

Can peptides replace resistance training for sarcopenia?

No, and the evidence is consistent on this point. Resistance training is the only intervention with reliable human evidence for improving both muscle mass and physical function in people with sarcopenia. Even the compounds with the strongest evidence in this guide work best alongside structured resistance exercise, not instead of it. The proposed value of peptide compounds is as a complement to training, particularly in addressing the anabolic resistance that makes aging muscle less responsive to exercise and protein alone. No compound in this guide has demonstrated the ability to substitute for exercise in producing functional outcomes.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for sarcopenia in one place.